VIJOICE Novartis Pharmaceuticals Australia Pty Ltd
Product name
VIJOICE
Accepted date
Jun-2026
Active ingredients
alpelisib
Summary of proposed indication
VIJOICE (alpelisib) is proposed to treat adults and children aged 2 years and older who have severe symptoms of PIK3CA-related overgrowth syndrome, also known as PROS. PROS is a group of rare genetic conditions that cause tissue overgrowth in multiple parts of the body.
Application type
C (new indication)
Publication date
Jun-2026
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.
Provisional registration
Involves early access to vital and life-saving medicines through time-limited registration.